Unilife Corporation, led by CEO Alan Shortall, is a U.S. based company that has developed a diversified portfolio of advanced drug delivery systems to accommodate the needs of biologics and other injectable drugs. Alan Shortall reports that the Company and its device portfolio has expanded rapidly in direct response to the needs of pharmaceutical companies, healthcare workers and patients.
According to Alan Shortall, the $200 billion market for injectable drugs and vaccines increasingly requires delivery systems that can serve as a primary container for the dose, and ensure its effective delivery to the target patient. Unilife is particularly targeting “biologics and other complex injectable drugs that require innovative devices that are developed or customized to address specific molecular requirements,” says Alan Shortall.
“Unilife recognizes that the safe and simple delivery of these doses is critical, with many injectable drugs now targeted for self-administration by patients outside of healthcare facilities. Furthermore, these emerging therapies are targeted for entry into highly competitive markets where novel, generic and biosimilar drugs all require some level of differentiation to succeed,” notes Alan Shortall.
Unilife’s Alan Shortall says that the Company specializes in innovative, differentiated devices that are developed or customized to address the specific needs of the pharmaceutical customer, the drug and the target patient. “That is what the pharmaceutical companies increasingly desire, and it’s something we are well positioned to provide here at Unilife,” Alan Shortall states.
Prefilled syringes with integrated safety features, auto-injectors with true end-of-dose indicators, wearable subcutaneous pump infusion systems, drug reconstitution delivery systems and novel devices for targeted organ delivery encompass some of the technology platforms within the fast-growing Unilife portfolio, according to CEO Alan Shortall.
“Unilife has one of the most complete and market-focused portfolios for injectable drug delivery available on the market,” reports Alan Shortall. The CEO says that Unilife has at the leading edge of its portfolio the Unifill syringe, the world’s first and only prefilled syringe with fully integrated safety features.
Initial production of the Unifill syringe, and its supply to pharmaceutical companies is now under way in York, PA according to Alan Shortall. “Unilife looks forward to entering into commercial supply contracts for the Unifill syringe with a number of pharmaceutical customers moving forward.”
Unilife, says Alan Shortall, is also securing strong interest in a related device called the Unifill Select.
“The Unifill Select is in many ways similar to the Unifill syringe. Its key difference is the use of attachable needs of up to 1.5 inches in length. That might seem like a small difference, but it has created some enormous commercial opportunities for Unilife,” adds Alan Shortall.
According to Alan Shortall, “Unilife has developed the Unifill Select so that operators can attach a needle at the point of injection. This makes the prefilled syringe ideal for use with many drugs and vaccines that require intramuscular injection.”
Unilife, says Alan Shortall has also developed other innovative devices including EZMix, the world’s first and only dual or multi-chamber prefilled syringe with integrated safety features and the Rita Auto-Injector, which features a true end-of-dose indicator,” concludes Alan Shortall.
Founded in Australia, Unilife still has offices in Sydney although they moved their main production facility to the United States in 2008. The company’s roots in Australia began when two inventors approached the firm’s future CEO Alan Shortall with a revolutionary idea. Shortall helped to found the medical device company that designs and distributes syringes and other injectable devices to pharmaceutical companies across the globe.
Unilife Australia Street Address
Suite 3, Level 11, 1 Chifley Square,
Sydney 2000 NSW Australia
Unilife Australia Postal Address
GPO Box 3400
Sydney 2001 NSW Australia
Tel: +612 8346 6500
Fax: +612 8346 6511